agilon health vs PACS
AGL and PACS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGL and PACS compare
PACS is the larger company, worth 4.0 times as much as agilon health ($7.7B against $1.9B).
PACS grew revenue faster over the last twelve months (15.2% versus 0.32% for agilon health).
PACS keeps more of each dollar of sales as profit, with a net margin of 4.8% compared with −3.9% at agilon health.
PACS scores higher on the StockData Score (12 against 4 for agilon health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGL | PACS |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $7.7B |
| Share price | $115.20 | $48.55 |
| Change, 1 year | 700% | 359% |
| Change, 5 years | −78.7% | – |
| Beta (5Y) | 5.41 | 0.65 |
| Employees | 856 | 47K |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 27.7× |
| P/S | 0.3× (better) | 1.4× |
| P/B | – | 6.9× |
| EV/EBITDA | – | 18.9× |
| PEG | – | 19.75 |
| FCF yield | −4.4% | – |
| Fair value | – | $39.49 |
| Margin of safety | – | −22.9% |
| Growth | ||
| Revenue growth (TTM) | 0.32% | 15.2% (better) |
| Revenue growth, 5Y average | 37.2% | – |
| Net income growth (TTM) | – | 104% |
| EPS growth (TTM) | – | 113% |
| Profitability | ||
| Gross margin | – | 23.5% |
| Operating margin | −5.2% | 7.4% (better) |
| Net margin | −3.9% | 4.8% (better) |
| FCF margin | −1.4% | – |
| Return on equity | – | 28.1% |
| Return on invested capital | – | 29.4% |
| Financial health | ||
| Debt / equity | – | 0.22 |
| Net debt / EBITDA | – | 0.20 |
| Interest coverage | −44.4× | 13.9× (better) |
| Current ratio | 1.08 (better) | 0.91 |
| Altman Z-score | 2.33 | 2.33 (better) |
| Piotroski F-score | 2 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.8% | 31.3% |
| Held by insiders | 10.1% | 78.5% |
| Insider net buying, 12 months | $300K (better) | −$119M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 5.6% | 12.6% |
Go deeper
- AGL stock overview
- AGL income statement
- AGL valuation and score
- PACS stock overview
- PACS income statement
- PACS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.